开云app官网登录入口网页版-官方正版

#BCL-2抑制剂#

17篇内容 | 1001人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1634994, encodeId=b5a116349943f, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂用于CLL/SLL前景无限, objectType=article, longId=212474, objectId=868f2124e4b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=868f2124e4b8, replyNumber=0, likeNumber=80, createdTime=2022-03-18, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=868f2124e4b8, moduleTitle=亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂用于CLL/SLL前景无限, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=868f2124e4b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634993, encodeId=1a21163499354, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号，用以治疗滤泡性淋巴瘤（FL）, objectType=article, longId=206517, objectId=375420651efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=375420651efe, replyNumber=0, likeNumber=59, createdTime=2021-02-27, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=375420651efe, moduleTitle=美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号，用以治疗滤泡性淋巴瘤（FL）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=375420651efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634990, encodeId=2fa4163499090, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定，治疗慢性淋巴细胞白血病, objectType=article, longId=200423, objectId=5feb2004238f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5feb2004238f, replyNumber=0, likeNumber=72, createdTime=2020-11-24, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5feb2004238f, moduleTitle=亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定，治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5feb2004238f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634986, encodeId=7c0d1634986c6, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床，获得NMPA的批准, objectType=article, longId=191730, objectId=1f9c191e301a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f9c191e301a, replyNumber=0, likeNumber=78, createdTime=2020-10-28, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f9c191e301a, moduleTitle=亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床，获得NMPA的批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1f9c191e301a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634992, encodeId=46a216349924a, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=全球上市BCL-2抑制剂维奈克拉在华获批, objectType=article, longId=204278, objectId=7b322042e8be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b322042e8be, replyNumber=0, likeNumber=68, createdTime=2021-07-15, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b322042e8be, moduleTitle=全球上市BCL-2抑制剂维奈克拉在华获批, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7b322042e8be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634987, encodeId=4b81163498ea9, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者, objectType=article, longId=193606, objectId=c7931936061f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7931936061f, replyNumber=0, likeNumber=85, createdTime=2021-01-03, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7931936061f, moduleTitle=加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c7931936061f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634991, encodeId=af8e1634991cd, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=BCL-2抑制剂Venclexta（venetoclax）获得FDA全面批准：用以治疗急性髓细胞性白血病（AML）, objectType=article, longId=202283, objectId=d69920228334, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d69920228334, replyNumber=0, likeNumber=79, createdTime=2021-09-28, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d69920228334, moduleTitle=BCL-2抑制剂Venclexta（venetoclax）获得FDA全面批准：用以治疗急性髓细胞性白血病（AML）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d69920228334)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634989, encodeId=33ee1634989fa, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=FDA授予Bcl-2抑制剂APG-2575孤儿药资格，用于治疗慢性淋巴细胞性白血病, objectType=article, longId=200404, objectId=d860200404a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d860200404a6, replyNumber=0, likeNumber=55, createdTime=2021-07-24, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d860200404a6, moduleTitle=FDA授予Bcl-2抑制剂APG-2575孤儿药资格，用于治疗慢性淋巴细胞性白血病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d860200404a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634985, encodeId=d55d163498523, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病, objectType=article, longId=190017, objectId=0f0519001e6d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f0519001e6d, replyNumber=0, likeNumber=74, createdTime=2021-01-31, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f0519001e6d, moduleTitle=BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0f0519001e6d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634988, encodeId=a570163498855, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=亚盛医药获得FDA授予第二个孤儿药称号：Bcl-2抑制剂APG-2575治疗华氏巨球蛋白血症, objectType=article, longId=197635, objectId=8f5319e6350c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f5319e6350c, replyNumber=0, likeNumber=88, createdTime=2021-05-28, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f5319e6350c, moduleTitle=亚盛医药获得FDA授予第二个孤儿药称号：Bcl-2抑制剂APG-2575治疗华氏巨球蛋白血症, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8f5319e6350c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634984, encodeId=b5f31634984d3, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价, objectType=article, longId=187245, objectId=3b7518e245e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b7518e245e4, replyNumber=0, likeNumber=74, createdTime=2020-12-06, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b7518e245e4, moduleTitle=对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3b7518e245e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634982, encodeId=fd23163498242, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者, objectType=article, longId=149701, objectId=7340149e01c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7340149e01c4, replyNumber=0, likeNumber=68, createdTime=2019-09-03, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7340149e01c4, moduleTitle=AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7340149e01c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634981, encodeId=3e30163498100, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=Eur J Pharmacol：Bcl-2抑制剂ABT-737在过敏性鼻炎模型中的抗过敏性和抗炎症作用研究, objectType=article, longId=140910, objectId=2bdb14091076, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bdb14091076, replyNumber=0, likeNumber=57, createdTime=2018-12-05, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bdb14091076, moduleTitle=Eur J Pharmacol：Bcl-2抑制剂ABT-737在过敏性鼻炎模型中的抗过敏性和抗炎症作用研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2bdb14091076)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634983, encodeId=fb85163498380, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=BCL-2抑制剂Venetoclax获NICE批准用于慢性淋巴细胞白血病, objectType=article, longId=158906, objectId=356b158906ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=356b158906ea, replyNumber=0, likeNumber=54, createdTime=2019-02-25, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=356b158906ea, moduleTitle=BCL-2抑制剂Venetoclax获NICE批准用于慢性淋巴细胞白血病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=356b158906ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634979, encodeId=10f116349e9d3, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=Blood：首次发现BCL-2抑制剂Venetoclax用于T幼淋巴细胞白血病患者可获得临床反应。, objectType=article, longId=114676, objectId=4ab01146e693, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ab01146e693, replyNumber=0, likeNumber=56, createdTime=2018-05-13, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ab01146e693, moduleTitle=Blood：首次发现BCL-2抑制剂Venetoclax用于T幼淋巴细胞白血病患者可获得临床反应。, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4ab01146e693)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634980, encodeId=91e816349808f, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=Blood：Venetoclax，BCL-2抑制剂，用于idelalisib治疗中或治疗后的CLL患者的效果和安全性。, objectType=article, longId=125904, objectId=387a125904d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=387a125904d3, replyNumber=0, likeNumber=69, createdTime=2018-08-04, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=387a125904d3, moduleTitle=Blood：Venetoclax，BCL-2抑制剂，用于idelalisib治疗中或治疗后的CLL患者的效果和安全性。, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=387a125904d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1634978, encodeId=4fdc16349e8d3, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, objectTitle=Leukemia：选择性Bcl-2抑制剂ABT-199临床试验证明对白血病疗效良好, objectType=article, longId=27984, objectId=83392e98476, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83392e98476, replyNumber=0, likeNumber=90, createdTime=2014-11-15, rootId=0, userName=ms3153534357578991, userId=f20922366212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83392e98476, moduleTitle=Leukemia：选择性Bcl-2抑制剂ABT-199临床试验证明对白血病疗效良好, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=83392e98476)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

BCL-2抑制剂

2020-05-29

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂用于CLL/SLL前景无限

2022-03-18

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号，用以治疗滤泡性淋巴瘤（FL）

2021-02-27

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定，治疗慢性淋巴细胞白血病

2020-11-24

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床，获得NMPA的批准

2020-10-28

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

全球上市BCL-2抑制剂维奈克拉在华获批

2021-07-15

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者

2021-01-03

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

BCL-2抑制剂Venclexta（venetoclax）获得FDA全面批准：用以治疗急性髓细胞性白血病（AML）

2021-09-28

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

FDA授予Bcl-2抑制剂APG-2575孤儿药资格，用于治疗慢性淋巴细胞性白血病

2021-07-24

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病

2021-01-31

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

亚盛医药获得FDA授予第二个孤儿药称号：Bcl-2抑制剂APG-2575治疗华氏巨球蛋白血症

2021-05-28

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价

2020-12-06

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者

2019-09-03

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

Eur J Pharmacol：Bcl-2抑制剂ABT-737在过敏性鼻炎模型中的抗过敏性和抗炎症作用研究

2018-12-05

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

BCL-2抑制剂Venetoclax获NICE批准用于慢性淋巴细胞白血病

2019-02-25

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

Blood：首次发现BCL-2抑制剂Venetoclax用于T幼淋巴细胞白血病患者可获得临床反应。

2018-05-13

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

Blood：Venetoclax，BCL-2抑制剂，用于idelalisib治疗中或治疗后的CLL患者的效果和安全性。

2018-08-04

ms3153534357578991 (审核中...)

前往app查看评论内容

#BCL-2抑制剂#

Leukemia：选择性Bcl-2抑制剂ABT-199临床试验证明对白血病疗效良好

2014-11-15

科室
- - 订阅+
  - 更多科室
工具
服务